{"id":"https://openalex.org/W2056844648","doi":"https://doi.org/10.1158/1538-7445.am2013-2066","title":"Abstract 2066: Combination therapy of human multiple myeloma using proteosome and CRM1 inhibitors.","display_name":"Abstract 2066: Combination therapy of human multiple myeloma using proteosome and CRM1 inhibitors.","publication_year":2013,"publication_date":"2013-04-01","ids":{"openalex":"https://openalex.org/W2056844648","doi":"https://doi.org/10.1158/1538-7445.am2013-2066","mag":"2056844648"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2013-2066","doi":"https://doi.org/10.1158/1538-7445.am2013-2066","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-2066","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033566009","display_name":"Joel G. Turner","orcid":"https://orcid.org/0009-0002-6081-3866","observed_orcids":["https://orcid.org/0009-0002-6081-3866","https://orcid.org/0000-0002-2358-6898"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel G. Turner","raw_affiliation_strings":["1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035721135","display_name":"Jana L. Dawson","orcid":"https://orcid.org/0000-0002-4901-0897","observed_orcids":["https://orcid.org/0000-0002-4901-0897"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jana L. Dawson","raw_affiliation_strings":["1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036862186","display_name":"Christopher L. Cubitt","orcid":"https://orcid.org/0000-0001-6343-7451","observed_orcids":["https://orcid.org/0000-0001-6343-7451"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher L. Cubitt","raw_affiliation_strings":["1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112906141","display_name":"Michael G. Kauffman","orcid":"https://orcid.org/0000-0001-5643-0200","observed_orcids":["https://orcid.org/0000-0001-5643-0200"]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Kauffman","raw_affiliation_strings":["2Karyopharm Therapeutics Inc, Natick, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Karyopharm Therapeutics Inc, Natick, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051352882","display_name":"Sharon Shacham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152529","display_name":"Karyopharm Therapeutics (United States)","ror":"https://ror.org/04ty78924","country_code":"US","type":"company","lineage":["https://openalex.org/I4210152529"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Shacham","raw_affiliation_strings":["2Karyopharm Therapeutics Inc, Natick, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Karyopharm Therapeutics Inc, Natick, MA","institution_ids":["https://openalex.org/I4210152529"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel M. Sullivan","raw_affiliation_strings":["1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1H. Lee Moffitt Cancer Ctr. & Res. Inst., Tampa, FL;","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"73","issue":"8_Supplement","first_page":"2066","last_page":"2066"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9670000076293945},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8500000238418579},{"id":"https://openalex.org/keywords/crm1-inhibitors","display_name":"CRM1 inhibitors","score":0.8379999995231628},{"id":"https://openalex.org/keywords/selective-inhibitor-of-nuclear-export","display_name":"selective inhibitor of nuclear export","score":0.8730000257492065},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9309999942779541},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/selinexor","display_name":"selinexor","score":0.781000018119812},{"id":"https://openalex.org/keywords/topoisomerase-ii-alpha","display_name":"TOP2A","score":0.8880000114440918},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.6200000047683716},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7820000052452087},{"id":"https://openalex.org/keywords/thalidomide","display_name":"thalidomide","score":0.6510000228881836}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7911837100982666},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.7846131324768066},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.6147369146347046},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5813624858856201},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.47847244143486023},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.46929436922073364},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4672185182571411},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.45359131693840027},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4517119526863098},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4492744207382202},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.4423040747642517},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.43697887659072876},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.4245270788669586},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.4237167239189148},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4225693345069885},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3475591838359833},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.20124804973602295},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.18467044830322266},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1438460350036621},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2013-2066","doi":"https://doi.org/10.1158/1538-7445.am2013-2066","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-2066","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7900000214576721,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1986593590","https://openalex.org/W2588056046","https://openalex.org/W2130287531","https://openalex.org/W2521396354","https://openalex.org/W2089476695","https://openalex.org/W2002403054","https://openalex.org/W2094088075","https://openalex.org/W1518659071","https://openalex.org/W2580124968","https://openalex.org/W2594504601"],"abstract_inverted_index":{"Abstract":[0],"Purpose.":[1],"Despite":[2],"improved":[3],"treatments":[4],"using":[5,468],"proteosome":[6,52,469],"inhibitor-":[7],"and":[8,57,69,105,122,147,167,213,237,254,257,263,290,308,322,330,353,358,372,384,401,407,427,470],"immunomodulator-based":[9],"(thalidomide)":[10],"therapies":[11],"human":[12,141,465],"multiple":[13,442,466],"myeloma":[14,467],"(MM)":[15],"still":[16],"remains":[17],"an":[18,120,198,438],"incurable":[19],"disease.":[20],"New":[21],"therapeutic":[22],"targets":[23],"or":[24,156,176,182,188,220],"unique":[25],"drug-combinations":[26],"are":[27],"needed":[28],"to":[29,37,88,207,270,399,414],"further":[30],"improve":[31],"treatment":[32,63,440],"outcomes.":[33],"Our":[34],"purpose":[35],"was":[36,268,412,422],"investigate":[38,208],"the":[39,45,115,127,134,243,336,477,482],"use":[40,116],"of":[41,44,80,117,126,136,210,230,261,319,464,476,481],"small-molecule":[42,393],"inhibitors":[43,53,98],"nuclear":[46,78,253,317],"export":[47,79,260,318],"(SINE)":[48],"in":[49,67,281,296,368,430],"combination":[50,297,363,434],"with":[51,83,149,172,184,298,356],"(PI),":[54],"bortezomib":[55],"(BTZ)":[56],"carfilzomib":[58],"(CFZ)":[59],"as":[60,325,350,378,403],"a":[61,106],"potential":[62],"for":[64,169,194,228,259,441,485],"MM":[65,86,142,153,157,224,305,310,369,374,397,431],"both":[66,287,304,320],"vitro":[68],"ex":[70],"vivo.":[71],"Methods.":[72],"Previously,":[73],"we":[74,95,113,139,339],"reported":[75],"that":[76,314,341,391],"blocking":[77],"topo":[81,89,264,323],"II\u03b1":[82,324],"SINE":[84,97,150,244,294,315,343],"sensitized":[85,396],"cells":[87,225,249,375,398],"II":[90],"poisons.":[91],"In":[92,111,215,274,417],"this":[93],"study,":[94],"used":[96,269,295],"developed":[99],"by":[100,197,232,286,327,332,380,405,424],"Karyopharm":[101],"Therapeutics,":[102],"KPT-185,":[103],"-249":[104],"new":[107],"clinical":[108],"compound":[109],"KPT-330.":[110],"addition":[112],"investigated":[114],"KOS-2464":[118,177],"(BMS),":[119],"effective":[121,302,439],"relatively":[123],"non-toxic":[124],"analog":[125],"known":[128],"CRM1":[129,276,394,419,471],"inhibitor":[130],"LMB.":[131],"To":[132,240],"test":[133],"efficacy":[135],"these":[137],"inhibitors,":[138,395],"treated":[140,168,217,248,283],"cell":[143,154,195,218,284,306,370,408],"lines,":[144],"RPMI-8226,":[145],"U266B1":[146],"NCI-H929":[148],"+/-":[151],"PI.":[152],"lines":[155,219,285,307],"patient":[158,223,309,373],"bone":[159],"marrow":[160],"aspirates":[161],"were":[162,191,205,226,250,279,300],"placed":[163],"at":[164],"high-density":[165],"conditions":[166],"20":[170],"hours":[171],"KPT-drugs":[173],"(300":[174],"nM)":[175],"(10":[178],"nM),":[179],"either":[180],"concurrently":[181],"sequentially":[183],"10-40":[185],"nM":[186],"BTZ":[187,357,400],"CFZ.":[189],"Cells":[190],"then":[192],"assayed":[193,227,258],"viability":[196,409],"automated":[199],"CellTiter-Blue":[200,337],"(Promega)":[201],"analysis.":[202],"Additional":[203],"experiments":[204],"performed":[206],"time-course":[209],"drug":[211],"action":[212],"dose-dependence.":[214],"addition,":[216,275,418],"CD138+/light":[221],"chain+":[222],"induction":[229],"apoptosis":[231,367,406],"cleaved":[233],"caspase":[234,381],"3":[235,382],"staining":[236,429],"flow":[238,385],"cytometry.":[239],"determine":[241],"if":[242],"blocked":[245,316],"CRM1-mediated":[246],"export,":[247],"separated":[251],"into":[252],"cytoplasmic":[255],"fractions":[256],"p53":[262,321],"II\u03b1.":[265],"Immunofluorescent":[266],"microscopy":[267],"confirm":[271],"fractionation":[272,329,426],"results.":[273],"expression":[277],"levels":[278],"measured":[280],"all":[282,342],"Western":[288],"blot":[289],"quantitative":[291],"PCR.":[292],"Results.":[293],"PI":[299],"highly":[301],"against":[303],"cells.":[311,432],"We":[312,389],"found":[313,340,390,413],"shown":[326,379,404],"nuclear/cytoplasmic":[328,425],"also":[331,365],"immunocytochemical":[333,428],"staining.":[334],"Using":[335],"assay,":[338],"tested":[344],"had":[345],"low":[346],"IC50":[347],"values":[348],"(nanomolar)":[349],"single":[351],"agents":[352],"functioned":[354],"synergistically":[355],"CFZ":[359,402],"(CI":[360],"<0.5).":[361],"SINE/PI":[362],"therapy":[364,435,463],"induced":[366],"cultures":[371],"(ex":[376],"vivo),":[377],"cleavage":[383],"cytometric":[386],"analyses.":[387],"Conclusions.":[388],"specific,":[392],"assays.":[410],"Sensitization":[411],"be":[415,437],"synergistic.":[416],"inhibiting":[420],"activity":[421],"verified":[423],"This":[433],"may":[436],"myeloma.":[443],"Citation":[444],"Format:":[445],"Joel":[446],"G.":[447],"Turner,":[448],"Jana":[449],"L.":[450,453],"Dawson,":[451],"Christopher":[452],"Cubitt,":[454],"Michael":[455],"Kauffman,":[456],"Sharon":[457],"Shacham,":[458],"Daniel":[459],"M.":[460],"Sullivan.":[461],"Combination":[462],"inhibitors.":[472],"[abstract].":[473],"In:":[474],"Proceedings":[475],"104th":[478],"Annual":[479],"Meeting":[480],"American":[483],"Association":[484],"Cancer":[486,496],"Research;":[487],"2013":[488],"Apr":[489],"6-10;":[490],"Washington,":[491],"DC.":[492],"Philadelphia":[493],"(PA):":[494],"AACR;":[495],"Res":[497],"2013;73(8":[498],"Suppl):Abstract":[499],"nr":[500],"2066.":[501],"doi:10.1158/1538-7445.AM2013-2066":[502]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}